APA (7th ed.) Citation

N, E., J, Z., J, T., H, E., J, L., X, B., . . . Y, G. (2025). Targeting ribonucleotide reductase to enhance the antileukemic activity of gilteritinib against chemoresistant FLT3- internal tandem duplication acute myeloid leukemia. ASPET discovery, 1, . https://doi.org/10.1016/j.aspetd.2025.100014

Chicago Style (17th ed.) Citation

N, Eid, et al. "Targeting Ribonucleotide Reductase to Enhance the Antileukemic Activity of Gilteritinib Against Chemoresistant FLT3- Internal Tandem Duplication Acute Myeloid Leukemia." ASPET Discovery 1 (2025). https://doi.org/10.1016/j.aspetd.2025.100014.

MLA (9th ed.) Citation

N, Eid, et al. "Targeting Ribonucleotide Reductase to Enhance the Antileukemic Activity of Gilteritinib Against Chemoresistant FLT3- Internal Tandem Duplication Acute Myeloid Leukemia." ASPET Discovery, vol. 1, 2025, https://doi.org/10.1016/j.aspetd.2025.100014.